Advertisement

Journal of Gastrointestinal Cancer

, Volume 48, Issue 3, pp 246–249 | Cite as

Surveillance of the Patients with High Risk of Hepatocellular Cancer

  • Necati ÖrmeciEmail author
Review Article
  • 81 Downloads

Hepatocellular carcinoma (HCC) is the fifth most common cancer among malignancies in men all over the world. It is the third most common leading cause of death. HCC accounts for more than 300,000 deaths in China and more than 650,000 deaths worldwide every year [1, 2, 3].

The only hope for curing HCC is to diagnose it at an early or very early stage. Local ablative treatments such as radiofrequency ablation and/or ethanol injection or resection lead to cure or long-term survival [4, 5]. However, patients diagnosed with advanced-stage HCC are usually treated by chemoembolization or chemotherapy, resulting in a much shorter life expectancy. In order to cure HCC or offer a longer life expectancy, surveillance of those patients with a high risk for HCC is necessary. There are several questions about the surveillance of patients with high risk for HCC. Firstly, is surveillance cost-effective? Secondly, can surveillance provide a diagnosis of HCC in the early stage? Thirdly, does...

Notes

Acknowledgements

The author is very thankful to Dr. Favzia Mai Tung for editing this article.

References

  1. 1.
    Singal A, Volk LM, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37–47.CrossRefGoogle Scholar
  2. 2.
    Ferenci P, Fried M, Labrecque D, et al. Hepatocellular carcinoma. A global perspective. J Clin Gastroenterol. 2010;44(4):1239–45.CrossRefGoogle Scholar
  3. 3.
    Davis GL, Dempster J, Meler JD, et al. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ med Cent). 2008;21(3):266–80.CrossRefGoogle Scholar
  4. 4.
    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–36.CrossRefGoogle Scholar
  5. 5.
    Intaraprosong P, Siramolpiwat S, Vilaichone RK, et al. Advances in management of hepatocellular carcinoma. Asian Pac J Cancer Prev. 2016;17(8):3697–703.Google Scholar
  6. 6.
    Lın COS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther. 2004;19:1159–72.CrossRefGoogle Scholar
  7. 7.
    Ting S, Shih F, Crowley S, Sheu JC. Cost-effectiveness analysis of a two-stage screening intervention for hepatocellular carcinoma in Taiwan. J Formos med Assoc. 2010;109(1):39–55.CrossRefGoogle Scholar
  8. 8.
    Andersson KL, Salomon JA, Chung RT, et al. Cost-effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6(12):1418–24.CrossRefGoogle Scholar
  9. 9.
    Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer res Clin Oncol. 2004;130:417–22.PubMedGoogle Scholar
  10. 10.
    Mcmahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 2000;32:842–6.CrossRefGoogle Scholar
  11. 11.
    Stravitz RT, Heuman DM, Chand N, et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J med. 2008;121:119–26.CrossRefGoogle Scholar
  12. 12.
    Kuo YH, Lu SN, Chen CL, et al. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer. 2010;46:744–51.CrossRefGoogle Scholar
  13. 13.
    Yeh YP, Hu TH, Cho PY, et al. Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan. Hepatology. 2014;59:1840–9.CrossRefGoogle Scholar
  14. 14.
    Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835–53.CrossRefGoogle Scholar
  15. 15.
    Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001;48:251–9.CrossRefGoogle Scholar
  16. 16.
    Yang HI, Yuen MF, Chan HLY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12:568–74.CrossRefGoogle Scholar
  17. 17.
    Michikawa T, Inoue M, Sawada N, et al. Development of a prediction model for 10-year risk of hepatocellular carcinoma in middle-aged Japanese: the Japan Public Health Center-based Prospective Study Cohort II. Prev med. 2012;55:137–43.CrossRefGoogle Scholar
  18. 18.
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.CrossRefGoogle Scholar
  19. 19.
    Yeoman AD, Al-Chalabi T, Karani JB. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow up and screening. Hepatology. 2008;48:863–70.CrossRefGoogle Scholar
  20. 20.
    Benson AB, Abrams TA, Ben-Josef E, et al. Hepatobiliary cancers: clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2009;7(4):350–91.CrossRefGoogle Scholar
  21. 21.
    Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439–74.CrossRefGoogle Scholar
  22. 22.
    Balogh J, Victor D III, Asham EH, et al. Hepatocellular carcinoma. A review. Journal of Hepatocellular Carcinoma. 2016;3:41–53.CrossRefGoogle Scholar
  23. 23.
    Wong VWS, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 28:1660–5.CrossRefGoogle Scholar
  24. 24.
    Flemming JA, Yang JD, Vittinghoff E, et al. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer. 2014;120(22):3485–93.CrossRefGoogle Scholar
  25. 25.
    El-Serag HB, Kanwal F, Davila JA, Kramer J, Richardson P. A new laboratory based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology. 2014;146(5):1249–55.CrossRefGoogle Scholar
  26. 26.
    Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol. 2010;28:2437–44.CrossRefGoogle Scholar
  27. 27.
    Yuen MF, Tanaka Y, Fong DYT, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50:80–8.CrossRefGoogle Scholar
  28. 28.
    Jung KS, Kim SU, Ahn SH, et al. Risk assessment of hepatitis B virus–related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011;53:885–94.CrossRefGoogle Scholar
  29. 29.
    Shin SH, Kim SU, Park JY, et al. Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis. Liver Int. 2015;35:1054–62.CrossRefGoogle Scholar
  30. 30.
    Chang KC, WuYY HCH, et al. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer. 2013;109:2481–8.CrossRefGoogle Scholar
  31. 31.
    Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C related advanced liver disease. Gastroenterology. 2009;136(1):138–48.CrossRefGoogle Scholar
  32. 32.
    Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49:1954–61.CrossRefGoogle Scholar
  33. 33.
    Chan AWH, Chan SL, Mo FKF, et al. Albumin-to-alkaline phosphatase ratio: a novel prognostic index for hepatocellular carcinoma. Hindawi Publishing Corporation Disease Markers Volume 2015, Article ID 564057, 10 pages.Google Scholar
  34. 34.
    Wong GLH, Chan HLY, Wong KYK, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol. 2014;60:339–45.CrossRefGoogle Scholar
  35. 35.
    Lu SN, Wang JH, Chen PF, et al. Community-based mass ultrasonographic screening of hepatocellular carcinoma among thrombocytopenic adults. Cancer Epidemiol Biomark Prev. 2008;17(7):1813–21.CrossRefGoogle Scholar
  36. 36.
    Kansagara D, Papak J, Pahsa AS, et al. Screening for hepatocellular carcinoma in chronic liver disease. A systematic review. Ann Intern med. 2014;161:261–9.CrossRefGoogle Scholar
  37. 37.
    Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J med Screen. 2003;10:204–9.CrossRefGoogle Scholar
  38. 38.
    Ungtrakul T, Mahidol C, Chun P, et al. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. World J Gastroenterol. 2016;22(34):7806–12.CrossRefGoogle Scholar
  39. 39.
    Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum a-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34:570–5.CrossRefGoogle Scholar
  40. 40.
    Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138(2):493.CrossRefGoogle Scholar
  41. 41.
    Zoli M, Magalotti D, Bianchi G, et al. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer. 1996;78:977–85.CrossRefGoogle Scholar
  42. 42.
    Tong MJ, Blatt LM, Kao VWC, et al. Chronic liver diseases: epidemiology, pathophysiology, diagnosis and treatment surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol. 2001;16:553–9.CrossRefGoogle Scholar
  43. 43.
    Singal AG, Conjeevaram HS, Volk ML. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomark Prev. 2012;21(5):793–9.CrossRefGoogle Scholar
  44. 44.
    Oka H, Saito A, Ito K, et al. Hepatocellular carcinoma and a-fetoprotein multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive a-fetoprotein1. J Gastroenterol Hepatol. 2001;16:1378–83.CrossRefGoogle Scholar
  45. 45.
    Coon JT, Rogers G, Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost–utility. Br J Cancer. 2008;98:1166–75.CrossRefGoogle Scholar
  46. 46.
    Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110–8.CrossRefGoogle Scholar
  47. 47.
    Pocha C, Dieperink E, McMaken KA, et al. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography—a randomised study. Aliment Pharmacol Ther. 2013;38:303–12.CrossRefGoogle Scholar
  48. 48.
    Sherman M, Bruix J, Morayko M, et al. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology. 2012;56(3):793–6.CrossRefGoogle Scholar
  49. 49.
    Saab S, Ly D, Nieto J, et al. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl. 2003;9:672–81.CrossRefGoogle Scholar
  50. 50.
    Trinchet JC, Chaffaut C, Bourcier VR, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011;54:1987–97.CrossRefGoogle Scholar
  51. 51.
    Han KH, Kim DY, Park JY, et al. Survival of hepatocellular carcinoma patients may be improved in surveillance interval not more than 6 months compared with more than 6 months. A 15-year prospective study. J Clin Gastroenterol. 2013;47:538–44.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of GastroenterologyAnkara University Medical SchoolAnkaraTurkey

Personalised recommendations